Medtronic (NYSE:MDT) Price Target Raised to $120.00

04 Apr 2026, 04:12 by Scott Moore · The Cerbat Gem

Medtronic (NYSE:MDT – Free Report) had its target price increased by Barclays from $118.00 to $120.00 in a report published on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the medical technology company’s stock.

A number of other brokerages have also commented on MDT. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Sanford C. Bernstein raised their target price on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. JPMorgan Chase & Co. reduced their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Finally, Piper Sandler decreased their price target on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.85.

View Our Latest Stock Report on MDT

Medtronic Stock Performance

Medtronic stock opened at $86.61 on Wednesday. The business has a 50 day moving average of $94.47 and a 200-day moving average of $96.22. The company has a market capitalization of $111.19 billion, a P/E ratio of 24.12, a P/E/G ratio of 2.24 and a beta of 0.75. Medtronic has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT – Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same period last year, the company earned $1.38 EPS. The firm’s revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts predict that Medtronic will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. Medtronic’s dividend payout ratio is 79.11%.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Purpose Unlimited Inc. bought a new stake in Medtronic in the fourth quarter worth approximately $8,182,000. Rockefeller Capital Management L.P. grew its stake in shares of Medtronic by 19.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 719,949 shares of the medical technology company’s stock valued at $69,159,000 after buying an additional 118,110 shares during the period. World Investment Advisors boosted its holdings in Medtronic by 5.7% in the fourth quarter. World Investment Advisors now owns 167,403 shares of the medical technology company’s stock worth $16,081,000 after acquiring an additional 8,961 shares in the last quarter. Winthrop Partners WNY LLC bought a new position in Medtronic in the fourth quarter worth approximately $1,223,000. Finally, Meadowbrook Advisors Group LLC acquired a new stake in Medtronic in the fourth quarter valued at approximately $2,156,000. 82.06% of the stock is owned by institutional investors and hedge funds.

About Medtronic

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.